Analytical Data
-
基因名
CYP51A1
- Application
-
别名
CYP51A1; CYP51; Lanosterol 14-alpha demethylase; LDM; CYPLI; Cytochrome P450 51A1; Cytochrome P450-14DM; Cytochrome P45014DM; Cytochrome P450LI; Sterol 14-alpha demethylase
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q16850
-
表达区间
1-509aa
-
氨基酸序列
MAAAAGMLLLGLLQAGGSVLGQAMEKVTGGNLLSMLLIACAFTLSLVYLIRLAAGHLVQLPAGVKSPPYIFSPIPFLGHAIAFGKSPIEFLENAYEKYGPVFSFTMVGKTFTYLLGSDAAALLFNSKNEDLNAEDVYSRLTTPVFGKGVAYDVPNPVFLEQKKMLKSGLNIAHFKQHVSIIEKETKEYFESWGESGEKNVFEALSELIILTASHCLHGKEIRSQLNEKVAQLYADLDGGFSHAAWLLPGWLPLPSFRRRDRAHREIKDIFYKAIQKRRQSQEKIDDILQTLLDATYKDGRPLTDDEVAGMLIGLLLAGQHTSSTTSAWMGFFLARDKTLQKKCYLEQKTVCGENLPPLTYDQLKDLNLLDRCIKETLRLRPPIMIMMRMARTPQTVAGYTIPPGHQVCVSPTVNQRLKDSWVERLDFNPDRYLQDNPASGEKFAYVPFGAGRHRCIGENFAYVQIKTIWSTMLRLYEFDLIDGYFPTVNYTTMIHTPENPVIRYKRRSK
-
分子量
57.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP51A1, a member of the cytochrome P450 superfamily of enzymes, is crucial for sterol biosynthesis, particularly in the synthesis of cholesterol and other sterols in eukaryotes and some prokaryotes. Its primary function involves catalyzing the conversion of lanosterol to episterol, a key step in the mevalonate pathway for sterol production. Research on CYP51A1 has gained significant attention due to its role in human health and disease, especially concerning lipid metabolism disorders and infectious diseases caused by fungi and parasites. In pathogens like fungi, CYP51A1 is often a target for antifungal drug discovery, as inhibiting this enzyme can disrupt ergosterol synthesis, essential for fungal cell membrane integrity. Additionally, understanding the structure and function of CYP51A1 through recombinant protein expression can facilitate the development of selective inhibitors with therapeutic potential. Advances in recombinant DNA technology have enabled the production of CYP51A1 in various expression systems, allowing researchers to study its enzymatic activity, substrate specificity, and interaction with potential inhibitors. This research not only helps elucidate the enzyme's biological role but also paves the way for novel pharmacological agents that can improve treatment strategies against infections and metabolic disorders linked to dysregulated sterol synthesis. Overall, studies on CYP51A1 are vital for advancing our understanding of both basic biological processes and their applications in medicine.
